



## Clinical trial results:

### Summary

EudraCT number	0007-004076-38
Trial protocol	SE FR BE CZ ES FI GB NL AT HU IT DE
Global end of trial date	

### Results information

Result version number	v1 (current)
This version publication date	
First version publication date	

### Trial information

#### Trial identification

Sponsor protocol code	
-----------------------	--

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

### Results analysis stage

Analysis stage	
Date of interim/final analysis	
Is this the analysis of the primary completion data?	
Global end of trial reached?	No

Notes:

---

**General information about the trial**

---

Main objective of the trial:

---

Protection of trial subjects:

---

Background therapy: -

---

Evidence for comparator: -

---

Actual start date of recruitment	
----------------------------------	--

---

Long term follow-up planned	No
-----------------------------	----

---

Independent data monitoring committee (IDMC) involvement?	
---	--

---

Notes:

---

**Population of trial subjects**

---

---

**Subjects enrolled per country**

---

Notes:

---

**Subjects enrolled per age group**

---

---

In utero	
----------	--

---

Preterm newborn - gestational age < 37 wk	
---	--

---

Newborns (0-27 days)	
----------------------	--

---

Infants and toddlers (28 days-23 months)	
--	--

---

Children (2-11 years)	
-----------------------	--

---

Adolescents (12-17 years)	
---------------------------	--

---

Adults (18-64 years)	
----------------------	--

---

From 65 to 84 years	
---------------------	--

---

85 years and over	
-------------------	--

---

## Subject disposition

---

### Recruitment

---

Recruitment details: -

---

### Pre-assignment

---

Screening details: -

## Baseline characteristics

## End points

---

### End points reporting groups

---

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

EudraCT tool TEST upload

Adverse event reporting additional description:

EudraCT tool TEST upload

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

### Reporting groups

Reporting group title	Group A
-----------------------	---------

Reporting group description: -

Reporting group title	Group C
-----------------------	---------

Reporting group description: -

Reporting group title	Group B
-----------------------	---------

Reporting group description: -

Serious adverse events	Group A	Group C	Group B
Total subjects affected by serious adverse events			
subjects affected / exposed	10 / 20 (50.00%)	9 / 18 (50.00%)	13 / 22 (59.09%)
number of deaths (all causes)	3	2	6
number of deaths resulting from adverse events	3	2	6
Injury, poisoning and procedural complications			
Ankle fracture	Additional description: Ankle fracture		
subjects affected / exposed	5 / 20 (25.00%)	7 / 18 (38.89%)	6 / 22 (27.27%)
occurrences causally related to treatment / all	5 / 6	9 / 14	4 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Activated partial thromboplastin time prolonged	Additional description: Activated partial thromboplastin time prolonged		
subjects affected / exposed	4 / 20 (20.00%)	5 / 18 (27.78%)	6 / 22 (27.27%)
occurrences causally related to treatment / all	4 / 8	4 / 9	6 / 11
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome	Additional description: Acute coronary syndrome		
subjects affected / exposed	3 / 20 (15.00%)	9 / 18 (50.00%)	4 / 22 (18.18%)
occurrences causally related to treatment / all	2 / 4	10 / 15	5 / 9

deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Congenital, familial and genetic disorders - Other, specify	Additional description: Congenital, familial and genetic disorders - Other, specify		
subjects affected / exposed	5 / 20 (25.00%)	9 / 18 (50.00%)	4 / 22 (18.18%)
occurrences causally related to treatment / all	4 / 5	9 / 14	7 / 11
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Blood and lymphatic system disorders			
Anemia	Additional description: Anemia		
subjects affected / exposed	6 / 20 (30.00%)	3 / 18 (16.67%)	7 / 22 (31.82%)
occurrences causally related to treatment / all	2 / 6	1 / 13	7 / 16
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Abducens nerve disorder	Additional description: Abducens nerve disorder		
subjects affected / exposed	5 / 20 (25.00%)	3 / 18 (16.67%)	6 / 22 (27.27%)
occurrences causally related to treatment / all	5 / 8	4 / 7	4 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Blurred vision	Additional description: Blurred vision		
subjects affected / exposed	6 / 20 (30.00%)	4 / 18 (22.22%)	3 / 22 (13.64%)
occurrences causally related to treatment / all	4 / 16	1 / 7	2 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Ear pain	Additional description: Ear pain		
subjects affected / exposed	2 / 20 (10.00%)	4 / 18 (22.22%)	6 / 22 (27.27%)
occurrences causally related to treatment / all	4 / 9	6 / 10	4 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal distension	Additional description: Abdominal distension		
subjects affected / exposed	7 / 20 (35.00%)	2 / 18 (11.11%)	3 / 22 (13.64%)
occurrences causally related to treatment / all	2 / 8	3 / 8	4 / 4
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury	Additional description: Acute kidney injury		
subjects affected / exposed	4 / 20 (20.00%)	0 / 18 (0.00%)	5 / 22 (22.73%)
occurrences causally related to treatment / all	3 / 5	0 / 0	2 / 9

deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Alopecia	Additional description: Alopecia		
subjects affected / exposed	3 / 20 (15.00%)	2 / 18 (11.11%)	8 / 22 (36.36%)
occurrences causally related to treatment / all	2 / 6	3 / 3	6 / 10
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Abdominal soft tissue necrosis	Additional description: Abdominal soft tissue necrosis		
subjects affected / exposed	5 / 20 (25.00%)	6 / 18 (33.33%)	4 / 22 (18.18%)
occurrences causally related to treatment / all	4 / 12	4 / 9	3 / 10
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Endocrine disorders			
Adrenal insufficiency	Additional description: Adrenal insufficiency		
subjects affected / exposed	5 / 20 (25.00%)	3 / 18 (16.67%)	12 / 22 (54.55%)
occurrences causally related to treatment / all	4 / 12	2 / 8	10 / 17
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Metabolism and nutrition disorders			
Acidosis	Additional description: Acidosis		
subjects affected / exposed	8 / 20 (40.00%)	2 / 18 (11.11%)	5 / 22 (22.73%)
occurrences causally related to treatment / all	2 / 10	5 / 9	3 / 15
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 2
Infections and infestations			
Abdominal infection	Additional description: Abdominal infection		
subjects affected / exposed	3 / 20 (15.00%)	4 / 18 (22.22%)	5 / 22 (22.73%)
occurrences causally related to treatment / all	3 / 7	4 / 10	1 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Capillary leak syndrome	Additional description: Capillary leak syndrome		
subjects affected / exposed	4 / 20 (20.00%)	9 / 18 (50.00%)	6 / 22 (27.27%)
occurrences causally related to treatment / all	8 / 12	10 / 16	1 / 11
deaths causally related to treatment / all	0 / 0	0 / 1	1 / 1
Surgical and medical procedures			
Surgical and medical procedures - Other, specify	Additional description: Surgical and medical procedures - Other, specify		
subjects affected / exposed	5 / 20 (25.00%)	3 / 18 (16.67%)	9 / 22 (40.91%)
occurrences causally related to treatment / all	3 / 5	4 / 7	9 / 16



deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Leukemia secondary to oncology chemotherapy	Additional description: Leukemia secondary to oncology chemotherapy		
subjects affected / exposed	5 / 20 (25.00%)	8 / 18 (44.44%)	4 / 22 (18.18%)
occurrences causally related to treatment / all	5 / 8	8 / 12	6 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	2 / 2
Immune system disorders			
Allergic reaction	Additional description: Allergic reaction		
subjects affected / exposed	7 / 20 (35.00%)	7 / 18 (38.89%)	8 / 22 (36.36%)
occurrences causally related to treatment / all	3 / 10	5 / 11	4 / 13
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Social circumstances			
Menopause	Additional description: Menopause		
subjects affected / exposed	8 / 20 (40.00%)	6 / 18 (33.33%)	6 / 22 (27.27%)
occurrences causally related to treatment / all	5 / 12	5 / 6	5 / 12
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Fetal death	Additional description: Fetal death		
subjects affected / exposed	3 / 20 (15.00%)	4 / 18 (22.22%)	5 / 22 (22.73%)
occurrences causally related to treatment / all	4 / 7	2 / 8	11 / 14
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chills	Additional description: Chills		
subjects affected / exposed	10 / 20 (50.00%)	6 / 18 (33.33%)	7 / 22 (31.82%)
occurrences causally related to treatment / all	12 / 20	3 / 14	14 / 17
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Agitation	Additional description: Agitation		
subjects affected / exposed	6 / 20 (30.00%)	2 / 18 (11.11%)	10 / 22 (45.45%)
occurrences causally related to treatment / all	4 / 8	6 / 12	9 / 15
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Azoospermia	Additional description: Azoospermia		
subjects affected / exposed	5 / 20 (25.00%)	4 / 18 (22.22%)	3 / 22 (13.64%)

occurrences causally related to treatment / all	6 / 11	4 / 9	2 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Adult respiratory distress syndrome	Additional description: Adult respiratory distress syndrome		
subjects affected / exposed	7 / 20 (35.00%)	5 / 18 (27.78%)	12 / 22 (54.55%)
occurrences causally related to treatment / all	10 / 17	5 / 12	12 / 22
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Bile duct stenosis	Additional description: Bile duct stenosis		
subjects affected / exposed	5 / 20 (25.00%)	1 / 18 (5.56%)	9 / 22 (40.91%)
occurrences causally related to treatment / all	1 / 5	0 / 6	8 / 16
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Group A	Group C	Group B
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 20 (50.00%)	11 / 18 (61.11%)	14 / 22 (63.64%)
Injury, poisoning and procedural complications			
Ankle fracture	Additional description: Ankle fracture		
subjects affected / exposed	5 / 20 (25.00%)	8 / 18 (44.44%)	4 / 22 (18.18%)
occurrences (all)	9	17	14
Investigations			
Activated partial thromboplastin time prolonged	Additional description: Activated partial thromboplastin time prolonged		
subjects affected / exposed	6 / 20 (30.00%)	2 / 18 (11.11%)	6 / 22 (27.27%)
occurrences (all)	8	7	14
Cardiac disorders			
Acute coronary syndrome	Additional description: Acute coronary syndrome		
subjects affected / exposed	4 / 20 (20.00%)	3 / 18 (16.67%)	11 / 22 (50.00%)
occurrences (all)	12	6	15
Congenital, familial and genetic disorders			
Congenital, familial and genetic disorders - Other, specify	Additional description: Congenital, familial and genetic disorders - Other, specify		
subjects affected / exposed	2 / 20 (10.00%)	7 / 18 (38.89%)	6 / 22 (27.27%)
occurrences (all)	4	7	11

Blood and lymphatic system disorders			
Anemia	Additional description: Anemia		
subjects affected / exposed	3 / 20 (15.00%)	5 / 18 (27.78%)	6 / 22 (27.27%)
occurrences (all)	10	11	14
Nervous system disorders			
Abducens nerve disorder	Additional description: Abducens nerve disorder		
subjects affected / exposed	7 / 20 (35.00%)	8 / 18 (44.44%)	8 / 22 (36.36%)
occurrences (all)	17	18	11
Eye disorders			
Blurred vision	Additional description: Blurred vision		
subjects affected / exposed	2 / 20 (10.00%)	8 / 18 (44.44%)	6 / 22 (27.27%)
occurrences (all)	7	16	9
Ear and labyrinth disorders			
Ear pain	Additional description: Ear pain		
subjects affected / exposed	8 / 20 (40.00%)	5 / 18 (27.78%)	7 / 22 (31.82%)
occurrences (all)	18	8	16
Gastrointestinal disorders			
Abdominal distension	Additional description: Abdominal distension		
subjects affected / exposed	7 / 20 (35.00%)	7 / 18 (38.89%)	8 / 22 (36.36%)
occurrences (all)	11	13	16
Renal and urinary disorders			
Acute kidney injury	Additional description: Acute kidney injury		
subjects affected / exposed	2 / 20 (10.00%)	5 / 18 (27.78%)	11 / 22 (50.00%)
occurrences (all)	7	11	21
Skin and subcutaneous tissue disorders			
Alopecia	Additional description: Alopecia		
subjects affected / exposed	4 / 20 (20.00%)	5 / 18 (27.78%)	5 / 22 (22.73%)
occurrences (all)	5	15	11
Musculoskeletal and connective tissue disorders			
Abdominal soft tissue necrosis	Additional description: Abdominal soft tissue necrosis		
subjects affected / exposed	4 / 20 (20.00%)	9 / 18 (50.00%)	3 / 22 (13.64%)
occurrences (all)	10	11	11
Endocrine disorders			
Adrenal insufficiency	Additional description: Adrenal insufficiency		
subjects affected / exposed	10 / 20 (50.00%)	4 / 18 (22.22%)	5 / 22 (22.73%)
occurrences (all)	18	4	11
Metabolism and nutrition disorders			

Acidosis subjects affected / exposed occurrences (all)	Additional description: Acidosis		
	6 / 20 (30.00%) 14	11 / 18 (61.11%) 18	5 / 22 (22.73%) 8
Infections and infestations Abdominal infection subjects affected / exposed occurrences (all)	Additional description: Abdominal infection		
	4 / 20 (20.00%) 9	3 / 18 (16.67%) 4	4 / 22 (18.18%) 14
Vascular disorders Capillary leak syndrome subjects affected / exposed occurrences (all)	Additional description: Capillary leak syndrome		
	2 / 20 (10.00%) 8	7 / 18 (38.89%) 8	5 / 22 (22.73%) 5
Surgical and medical procedures Surgical and medical procedures - Other, specify subjects affected / exposed occurrences (all)	Additional description: Surgical and medical procedures - Other, specify		
	6 / 20 (30.00%) 15	4 / 18 (22.22%) 14	4 / 22 (18.18%) 10
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Leukemia secondary to oncology chemotherapy subjects affected / exposed occurrences (all)	Additional description: Leukemia secondary to oncology chemotherapy		
	4 / 20 (20.00%) 5	5 / 18 (27.78%) 14	4 / 22 (18.18%) 13
Immune system disorders Allergic reaction subjects affected / exposed occurrences (all)	Additional description: Allergic reaction		
	4 / 20 (20.00%) 5	3 / 18 (16.67%) 8	9 / 22 (40.91%) 17
Social circumstances Menopause subjects affected / exposed occurrences (all)	Additional description: Menopause		
	8 / 20 (40.00%) 14	1 / 18 (5.56%) 3	7 / 22 (31.82%) 7
Pregnancy, puerperium and perinatal conditions Fetal death subjects affected / exposed occurrences (all)	Additional description: Fetal death		
	4 / 20 (20.00%) 7	6 / 18 (33.33%) 7	14 / 22 (63.64%) 22
General disorders and administration site conditions Chills subjects affected / exposed occurrences (all)	Additional description: Chills		
	3 / 20 (15.00%) 6	10 / 18 (55.56%) 15	5 / 22 (22.73%) 8
Psychiatric disorders			

Agitation subjects affected / exposed occurrences (all)	Additional description: Agitation		
	5 / 20 (25.00%) 5	7 / 18 (38.89%) 8	4 / 22 (18.18%) 7
Reproductive system and breast disorders Azoospermia subjects affected / exposed occurrences (all)	Additional description: Azoospermia		
	8 / 20 (40.00%) 16	6 / 18 (33.33%) 11	6 / 22 (27.27%) 15
Respiratory, thoracic and mediastinal disorders Adult respiratory distress syndrome subjects affected / exposed occurrences (all)	Additional description: Adult respiratory distress syndrome		
	4 / 20 (20.00%) 7	8 / 18 (44.44%) 14	3 / 22 (13.64%) 6
Hepatobiliary disorders Bile duct stenosis subjects affected / exposed occurrences (all)	Additional description: Bile duct stenosis		
	4 / 20 (20.00%) 7	3 / 18 (16.67%) 9	8 / 22 (36.36%) 16

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol?

---

### Interruptions (globally)

Were there any global interruptions to the trial?

### Limitations and caveats

None reported